Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
UBS
US Army
Citi
Baxter
Mallinckrodt
Medtronic
Argus Health
Chubb
Chinese Patent Office

Generated: October 23, 2017

DrugPatentWatch Database Preview

Takeda Pharms Usa Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?

TAKEDA PHARMS USA has seventeen approved drugs.

There are eighty-two US patents protecting TAKEDA PHARMS USA drugs and there have been two Paragraph IV challenges on TAKEDA PHARMS USA drugs in the past three years.

There are one thousand and sixty-eight patent family members on TAKEDA PHARMS USA drugs in fifty-nine countries and one hundred and twenty-eight supplementary protection certificates in fifteen countries.

Summary for Applicant: Takeda Pharms Usa

International Patents:1068
US Patents:82
Tradenames:17
Ingredients:14
NDAs:17
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
TRINTELLIX
vortioxetine hydrobromide
TABLET;ORAL204447-004Sep 30, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
ACTOPLUS MET XR
metformin hydrochloride; pioglitazone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022024-001May 12, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
NESINA
alogliptin benzoate
TABLET;ORAL022271-002Jan 25, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
KAZANO
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
TRINTELLIX
vortioxetine hydrobromide
TABLET;ORAL204447-001Sep 30, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
NESINA
alogliptin benzoate
TABLET;ORAL022271-001Jan 25, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
ACTOPLUS MET XR
metformin hydrochloride; pioglitazone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022024-001May 12, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Takeda Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa
KAZANO
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
NESINA
alogliptin benzoate
TABLET;ORAL022271-003Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-004Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-005Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-003Jul 15, 1999► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-002Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TAKEDA PHARMS USA drugs

Drugname Dosage Strength Tradename Submissiondate
alogliptin and metformin hydrochloride
Tablets12.5 mg/500 mg and 12.5 mg/1000 mg
KAZANO
1/25/2017
alogliptin
Tablets6.25 mg, 12.5 mg and 25 mg
NESINA
1/25/2017
febuxostat
Tablets40 mg and 80 mg
ULORIC
2/13/2013
colchicine
Tablets0.6 mg
COLCRYS
12/23/2011
pioglitazone hydrochloride and metformin hydrochloride
Extended-release Tablets15 mg/1000 mg and 30 mg/1000 mg
ACTOPLUS MET XR
9/23/2011
dexlansoprazole
Delayed-release Capsule30 mg
DEXILANT
11/30/2010
dexlansoprazole
Capsule60 mg
DEXILANT
8/25/2010
pioglitazone hydrochloride and glimepiride
Tablets30 mg/2 mg and 30 mg/4 mg
DUETACT
12/22/2009
ramelteon
Tablets8 mg
ROZEREM
7/22/2009
pioglitazone hydrochloride and metformin hydrochloride
Tablets15 mg/500 mg and 15 mg/850 mg
ACTOPLUS MET
3/6/2008
lansoprazole
Delayed-release Orally Disinte15 mg and 30 mg
PREVACID
12/27/2006
lansoprazole
Delayed-release Pellets/Capsul15 mg and 30 mg
PREVACID
12/5/2005

Non-Orange Book Patents for Takeda Pharms Usa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,211,205 Pharmaceutical composition► Subscribe
8,729,030Peptides that bind to the erythropoietin receptor► Subscribe
7,683,053Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
9,125,9101-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment► Subscribe
8,309,125Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
6,599,923 Pharmaceutical composition► Subscribe
8,592,365Spacer moiety for poly(ethylene glycol) modified peptide based compounds► Subscribe
8,664,2251-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition► Subscribe
7,795,428Dipeptidyl peptidase inhibitors► Subscribe
6,274,605 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Takeda Pharms Usa Drugs

Country Document Number Estimated Expiration
Singapore160224► Subscribe
SloveniaEP1956015► Subscribe
Japan5881962► Subscribe
Denmark0885210► Subscribe
World Intellectual Property Organization (WIPO)2007144005► Subscribe
Japan2013173763► Subscribe
Eurasian Patent Organization013427► Subscribe
Eurasian Patent Organization200970018► Subscribe
Australia2493599► Subscribe
Japan2005263780► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Takeda Pharms Usa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00569Netherlands► SubscribePRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
C015/2010Ireland► SubscribeSPC015/2010: 20101001, EXPIRES: 20230420
1084705/05Switzerland► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013
/2010Austria► SubscribePRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
0861666/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
1129088/01Switzerland► SubscribePRODUCT NAME: DEXLANSOPARAZOL; REGISTRATION NO/DATE: SWISSMEDIC 62993 09.05.2014
2014044Lithuania► SubscribePRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
C 038/2006Ireland► SubscribeSPC 038/2006: 20070528, EXPIRES: 20210619
2014013,C1436271Lithuania► SubscribePRODUCT NAME: VORTIOKSETINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA RUGSTIES PRISIJUNGIMO DRUSKA; REGISTRATION NO/DATE: EU/1/13/891 20131218
C0008France► SubscribePRODUCT NAME: VILDAGLIPTINE OU UN DE SES SELS PHARMACETIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/414/001 DU 20070926; REGISTRATION NO/DATE AT EEC: EU/1/07/414/001-017 DU 20070926
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Harvard Business School
Mallinckrodt
Moodys
Argus Health
UBS
QuintilesIMS
US Department of Justice
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot